391 related articles for article (PubMed ID: 19117887)
1. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I.
Clarke LA; Wraith JE; Beck M; Kolodny EH; Pastores GM; Muenzer J; Rapoport DM; Berger KI; Sidman M; Kakkis ED; Cox GF
Pediatrics; 2009 Jan; 123(1):229-40. PubMed ID: 19117887
[TBL] [Abstract][Full Text] [Related]
2. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase).
Wraith JE; Beck M; Lane R; van der Ploeg A; Shapiro E; Xue Y; Kakkis ED; Guffon N
Pediatrics; 2007 Jul; 120(1):e37-46. PubMed ID: 17606547
[TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).
Wraith JE; Clarke LA; Beck M; Kolodny EH; Pastores GM; Muenzer J; Rapoport DM; Berger KI; Swiedler SJ; Kakkis ED; Braakman T; Chadbourne E; Walton-Bowen K; Cox GF
J Pediatr; 2004 May; 144(5):581-8. PubMed ID: 15126990
[TBL] [Abstract][Full Text] [Related]
4. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years.
Sifuentes M; Doroshow R; Hoft R; Mason G; Walot I; Diament M; Okazaki S; Huff K; Cox GF; Swiedler SJ; Kakkis ED
Mol Genet Metab; 2007 Feb; 90(2):171-80. PubMed ID: 17011223
[TBL] [Abstract][Full Text] [Related]
5. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
Jameson E; Jones S; Remmington T
Cochrane Database Syst Rev; 2016 Apr; 4():CD009354. PubMed ID: 27033167
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement therapy with laronidase (Aldurazyme(®)) for treating mucopolysaccharidosis type I.
Jameson E; Jones S; Wraith JE
Cochrane Database Syst Rev; 2013 Nov; (11):CD009354. PubMed ID: 24257962
[TBL] [Abstract][Full Text] [Related]
7. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase.
Harmatz P; Ketteridge D; Giugliani R; Guffon N; Teles EL; Miranda MC; Yu ZF; Swiedler SJ; Hopwood JJ;
Pediatrics; 2005 Jun; 115(6):e681-9. PubMed ID: 15930196
[TBL] [Abstract][Full Text] [Related]
8. Enzyme replacement therapy with laronidase (Aldurazyme) for treating mucopolysaccharidosis type I.
Jameson E; Jones S; Wraith JE
Cochrane Database Syst Rev; 2013 Sep; (9):CD009354. PubMed ID: 24085657
[TBL] [Abstract][Full Text] [Related]
9. Enzyme-replacement therapy in mucopolysaccharidosis I.
Kakkis ED; Muenzer J; Tiller GE; Waber L; Belmont J; Passage M; Izykowski B; Phillips J; Doroshow R; Walot I; Hoft R; Neufeld EF
N Engl J Med; 2001 Jan; 344(3):182-8. PubMed ID: 11172140
[TBL] [Abstract][Full Text] [Related]
10. A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I.
Giugliani R; Rojas VM; Martins AM; Valadares ER; Clarke JT; Góes JE; Kakkis ED; Worden MA; Sidman M; Cox GF
Mol Genet Metab; 2009 Jan; 96(1):13-9. PubMed ID: 19038563
[TBL] [Abstract][Full Text] [Related]
11. Enzyme replacement therapy with laronidase (Aldurazyme
Jameson E; Jones S; Remmington T
Cochrane Database Syst Rev; 2019 Jun; 6(6):CD009354. PubMed ID: 31211405
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome).
Muenzer J; Gucsavas-Calikoglu M; McCandless SE; Schuetz TJ; Kimura A
Mol Genet Metab; 2007 Mar; 90(3):329-37. PubMed ID: 17185020
[TBL] [Abstract][Full Text] [Related]
13. Laronidase.
BioDrugs; 2002; 16(4):316-8. PubMed ID: 12196045
[TBL] [Abstract][Full Text] [Related]
14. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study.
Harmatz P; Giugliani R; Schwartz I; Guffon N; Teles EL; Miranda MC; Wraith JE; Beck M; Arash L; Scarpa M; Yu ZF; Wittes J; Berger KI; Newman MS; Lowe AM; Kakkis E; Swiedler SJ;
J Pediatr; 2006 Apr; 148(4):533-539. PubMed ID: 16647419
[TBL] [Abstract][Full Text] [Related]
15. Alpha-L-iduronidase (laronidase; aldurazyme).
Med Lett Drugs Ther; 2003 Oct; 45(1168):88. PubMed ID: 14576624
[No Abstract] [Full Text] [Related]
16. Outcomes of Long-Term Treatment with Laronidase in Patients with Mucopolysaccharidosis Type I.
Laraway S; Mercer J; Jameson E; Ashworth J; Hensman P; Jones SA
J Pediatr; 2016 Nov; 178():219-226.e1. PubMed ID: 27788836
[TBL] [Abstract][Full Text] [Related]
17. Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I.
Dickson PI; Kaitila I; Harmatz P; Mlikotic A; Chen AH; Victoroff A; Passage MB; Madden J; Le SQ; Naylor DE;
Mol Genet Metab; 2015; 116(1-2):69-74. PubMed ID: 26260077
[TBL] [Abstract][Full Text] [Related]
18. Alternative laronidase dose regimen for patients with mucopolysaccharidosis I: a multinational, retrospective, chart review case series.
Horovitz DD; Acosta AX; Giugliani R; Hlavatá A; Hlavatá K; Tchan MC; Lopes Barth A; Cardoso L; Embiruçu de Araújo Leão EK; Esposito AC; Kyosen SO; De Souza CF; Martins AM
Orphanet J Rare Dis; 2016 Apr; 11(1):51. PubMed ID: 27129473
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: A systematic review and meta-analysis.
Dornelles AD; Artigalás O; da Silva AA; Ardila DLV; Alegra T; Pereira TV; Vairo FPE; Schwartz IVD
PLoS One; 2017; 12(8):e0184065. PubMed ID: 28859139
[TBL] [Abstract][Full Text] [Related]
20. [Hurler syndrome. Early diagnosis and successful enzyme replacement therapy: a new therapeutic approach. Case report].
Dupont C; El Hachem C; Harchaoui S; Ribault V; Amiour M; Guillot M; Maire I; Froissart R; Guffon-Fouilhoux N
Arch Pediatr; 2008 Jan; 15(1):45-9. PubMed ID: 18162380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
